Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419612 | 1.00 | GABRA1 (0.41) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL1741996 | 1.00 | GABRA1 (0.41) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL11606150 | 0.81 | CYP3A4 (0.44) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL29528605 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL251913 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL251914 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL253024 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL253023 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 | |
| SCHEMBL28449368 | 0.81 | GABRA1 (0.39) | GABRA1GABRB2CYP3A4SLC6A2HTR2C | |
| SCHEMBL29528763 | 0.81 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655291-A2 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS BACKGROUND | Merck Sharp & Dohme LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024158653-A2 | N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS BACKGROUND | MERCK SHARP & DOHME LLC (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-2770995-B1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2770995-B1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9624208-B2 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624208-B2 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624208-B2 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2017032887-A1 | METHOD FOR PRODUCING SILICONIZED, W/O PICKERING EMULSION-FORMING PARTICLES, AND USE THEREOF | Technische Universität Dresden (DE) | 2017-03-02 | — | — | WO | disclosed |
| EP-2822953-B1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-7217740-B2 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP AND DOHME | 2007-05-15 | — | — | US | disclosed |
| WO-2007036570-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007020221-A2 | AMINO-PHOSPHINOALKYL-FERROCENES AND THEIR USE AS LIGANDS IN CATALYSTS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006068879-A1 | TETRADENTATE LIGANDS AND METAL COMPLEXES THEREOF FOR ASYMMETRIC CATALYSIS | EASTMAN CHEMICAL COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006046062-A1 | PROCESS FOR THE DE-ENRICHMENT OF ENANTIOMERICALLY ENRICHED SUBSTRATES | AVECIA PHARMACEUTICALS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2006-03-09 | — | — | US | disclosed |
| WO-2006021806-A1 | ARYLSULPHONYLSTILBENE DERIVATIVES FOR TREATMENT OF INSOMNIA AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021805-A1 | DIARYLSULFONES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| EP-1222163-A1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001025189-A1 | 2'-SUBSTITUTED 1,1'-BIPHENYL-2-CARBONAMIDES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052445-A1 | Diarylsulfones as 5-HT2A antagonists | HTR2A, HTR2B, HTR1A | GABRA1 381/4885GABRB2 322/4885CYP3A4 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.